Physician profile
Charles E Thomas
NPI 1497715619
$6,333.97
in general payments reported to CMS, 2019-2025
23 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $446 · 2021: $764 · 2022: $1,414 · 2023: $1,103 · 2024: $1,098 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $926.84 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $856.36 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $671.86 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $505.24 | 2022-2025 | Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $394.47 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $351.47 | 2019-2021 | |
| Allergan, INC. | $286.58 | 2019-2022 | |
| Glaukos Corporation | $283.56 | 2022 | |
| Optos, INC. | $260.21 | 2020-2022 | |
| Harrow Eye, LLC | $259.77 | 2024-2025 | Vevye |
| Dompe US, INC. | $251.51 | 2023-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $236.46 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $201.91 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $190.87 | 2020-2021 | |
| Rxsight INC | $135.83 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $117.65 | 2024 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Kala Pharmaceuticals, INC. | $88.19 | 2021 | |
| Lkc Technologies, INC. | $80.04 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $76.46 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $65.96 | 2019 | |
| Apellis Pharmaceuticals, INC. | $51.57 | 2025 | |
| Astellas Pharma US INC | $21.53 | 2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $19.63 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.